Antoine GUEGUEN
Paris, France
NCT Number: NCT04465084
Multiple sclerosis (MS) is an autoimmune disease of the central nervous systems that results in focal inflammatory lesions and then diffuse and degenerative inflammatory phenomena. It is considered to be the leading cause of non-traumatic disability in young adults.
Cognitive impairment is a common and disabling part of MS. Studies carried out in the years 1990-2000 estimated their frequency to be between 40 and 60% of MS patients: they reflect the natural history of the disease. Effective treatments for the inflammatory component of the disease that are now available may have led to a reduction in their frequency.
Cognitive disorders were identified at an early stage of the disease and affect certain areas preferentially:
* The most common achievement is the reduction in the speed of information processing. It is present from the early stage of the disease. Progressive deterioration over time is observed, which is a prognostic factor for long-term cognitive decline.
Long-term memory was impaired in 40-65% of patients in historical cohorts. More specifically, encoding and retrieval were affected, with storage and consolidation being preserved.
* The attainment of executive functions is also common. * Phonemic and semantic fluency are also disturbed in MS patients. Among cognitive impairments, language impairment has been little studied in MS: in 2016 only 22 controlled studies were identified. The assessments carried out were most often partial, making it impossible to define the characteristics or to conclude that specific linguistic impairments are independent of other cognitive impairments. Finally, recent studies suggest that the frequency of language impairment in MS may be underestimated.
Therefore, it seems important to assess the prevalence of language disorders in a large cohort of patients with RRMS or MS, and to characterize these disorders by identifying the linguistic processes involved and the brain substrates involved. This will make it possible to envisage the implementation of more systematic screening for language disorders in MS and to improve patient management, in particular by developing targeted rehabilitation protocols.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Not applicable
Paris, France
Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis.
Experimental tasks based on psycholinguistics and functional MRI are not standardized tests. To be able to interpret the results of patients, they must therefore be compared with healthy controls of the same age (+/-3 years) and level of education.
This study will require the inclusion of cases and controls matched to these cases on the above characteristics.
Patients who are seen in consultation or day hospitalization and who meet the inclusion and non-inclusion criteria will be offered the opportunity to participate in the study. Accompanying persons accompanying patients "matching" with included patients who meet the inclusion and non-inclusion criteria will also be offered the opportunity to participate in the study.
Inclusion visit (D0) :
Visit 1 (assessment in HDJ) (D0 + 6 months maximum) :
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Criteria for inclusion of cases :
Criteria for non-inclusion of cases
Criteria for inclusion of witnesses
Criteria for non-inclusion of witnesses
Battery of standardised and normalised tests evaluating different cognitive functions Experimental language tasks MRI
Experimental language tasks MRI
Time frame: 6 month
Fondation Ophtalmologique Adolphe de Rothschild
Network
Acronym: LANSEP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04786821
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Sheffield, South Yorkshire, United Kingdom
View Trial DetailsNCT04539002
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Portland, Oregon, United States
View Trial DetailsNCT00114530
Autoimmune Disease, Autoimmune Diseases
Duarte, California, United States
View Trial DetailsNCT01495390
ALS, Amyotrophic Lateral Sclerosis
Phoenix, Arizona, United States
View Trial Details